Solid Tumor Targeting CAR-T Development Service: Depletion of MDSC & Treg

Creative Biolabs' Solid Tumor Targeting CAR-T Development Service provides an integrated solution for reversing immune suppression through targeted depletion of Myeloid-Derived Suppressor Cells (MDSCs) and Regulatory T cells (Tregs). Featuring advanced genetic engineering strategies and dual-targeting modalities, this service enhances CAR-T persistence and reinvigorates anti-tumor activity within the hostile Tumor Microenvironment (TME). By reprogramming the immunosuppressive environment into an active immune state, it empowers researchers to achieve durable efficacy and accelerate the development of next-generation solid tumor CAR-T therapies.

Introduction

CAR-T cell therapy has achieved remarkable success in hematological malignancies, but equivalent results in solid tumors are limited by the hostile TME. The TME is a major roadblock, characterized by physical barriers, metabolic dysfunction, and intense immunosuppression. Key culprits in this suppression are MDSCs and Tregs, which actively inhibit CAR-T proliferation and function, leading to T-cell exhaustion.

Fig.1 The immunosuppressive tumor microenvironment.¹

Creative Biolabs' Service

The successful deployment of CAR-T cells in solid tumors requires directly countering the TME, where MDSCs and Tregs act as central architects of immune evasion. Creative Biolabs specializes in arming your CAR-T cells with next-generation capabilities designed to neutralize these immunosuppressive populations, shifting the "cold" TME to a "hot", highly infiltrated anti-tumor environment. Solid tumors create a highly immunosuppressive environment where MDSCs and Tregs inhibit CAR‑T proliferation and cytotoxicity. Our service integrates cutting-edge CAR‑T engineering with TME modulation to enhance efficacy, persistence, and tumor infiltration.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Our service provides targeted immunosuppression remodeling by engineering T-cells to convert TGF-β suppression into activation and selectively induce MDSC apoptosis, incorporates targeting strategies to reduce off-target toxicity while sparing normal T-cells, and is supported by validated preclinical models demonstrating enhanced CAR-T function and extended survival in multiple cancer types.

Our Workflow

The final deliverables include the optimized CAR-T vector with the immunosuppressive cell depletion cassette, a comprehensive T-cell product report with phenotypic and functional data, and proof-of-concept efficacy data demonstrating MDSC depletion and enhanced cytotoxicity.

Core Benefits

• Expertise in solid tumor CAR‑T and TME modulation
• Customizable modules for MDSC/Treg targeting
• Seamless integration from design to preclinical validation
• Regulatory-aware, safe, and reproducible workflows

FAQs

Partner with Us

Creative Biolabs delivers industry-leading solutions for next-generation CAR-T therapy by focusing on the crucial step of TME remodeling. Our Solid Tumor Targeting CAR-T Development Service: Depletion of MDSC & Treg offers genetically engineered T-cells designed to disarm the core immunosuppressive network, maximizing efficacy and durability in the hostile solid tumor environment. Ready to discuss how targeted MDSC/Treg depletion can revolutionize your solid tumor CAR-T program? Our specialized team is prepared to tailor a strategic and technical plan to your unique scientific needs. Contact us today to start the conversation.

Reference

1. Jaing, Tang-Her et al. “Chimeric Antigen Receptor Cell Therapy: Empowering Treatment Strategies for Solid Tumors.” Current issues in molecular biology vol. 47,2 90. 31 Jan. 2025. Distributed under Open Access License CC BY 4.0, without modification. https://doi.org/10.3390/cimb47020090